Morgan Stanley Regencell Bioscience Holdings LTD Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$12.18 - $23.04 $304 - $576	25 Added 8.31%	326 $4,000
Q2 2023 Aug 14, 2023	BUY	$21.67 - $29.88 $86 - $119	4 Added 1.35%	301 $6,000
Q1 2023 May 15, 2023	BUY	$25.23 - $30.19 $403 - $483	16 Added 5.69%	297 $7,000
Q4 2022 Feb 14, 2023	BUY	$25.52 - $31.8 $1,378 - $1,717	54 Added 23.79%	281 $7,000
Q3 2022 Nov 14, 2022	BUY	$26.94 - $40.8 $2,101 - $3,182	78 Added 52.35%	227 $7,000
Q2 2022 Oct 27, 2022	BUY	$20.67 - $45.78 $2,955 - $6,546	143 Added 2383.33%	149 $5,000
Q2 2022 Aug 15, 2022	BUY	$20.67 - $45.78 $2,955 - $6,546	143 Added 2383.33%	149 $5,000
Q1 2022 Oct 27, 2022	SELL	$21.4 - $40.0 $3,060 - $5,720	-143 Reduced 95.97%	6 $0
Q1 2022 May 13, 2022	BUY	$21.4 - $40.0 $128 - $240	6 New	6 $0
Q4 2021 Feb 14, 2022	SELL	$13.43 - $32.87 $6,755 - $16,533	-503 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.3 - $46.33 $3,168 - $23,303	503 New	503 $11,000

18.1K

Ticker RGC
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,012,900
Market Cap $66.6M
Description
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.